RhumbLine Advisers’s Capricor Therapeutics CAPR Stock Holding History

RhumbLine Advisers’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$619K	Sell	65,395 -2,486	-4%	-$27.5K	﹤0.01%	2598
2026 Q2	$1.63M	Buy	67,881 +15,798	+30%	+$479K	﹤0.01%	2053
2026 Q1	$1.58M	Buy	52,083 +5,106	+11%	+$136K	﹤0.01%	1977
2025 Q4	$1.36M	Sell	46,977 -3,902	-8%	-$51K	﹤0.01%	2070
2025 Q3	$367K	Sell	50,879 -2,571	-5%	-$18.9K	﹤0.01%	2883
2025 Q2	$531K	Buy	53,450 +3,636	+7%	+$38.4K	﹤0.01%	2653
2025 Q1	$473K	Buy	49,814 +3,731	+8%	+$51.8K	﹤0.01%	2613
2024 Q4	$636K	Buy	46,083 +14,169	+44%	+$248K	﹤0.01%	2514
2024 Q3	$485K	Buy	31,914 +1,028	+3%	+$5.08K	﹤0.01%	2714
2024 Q2	$147K	Buy	+30,886	New	+$172K	﹤0.01%	3386

Other funds holding CAPR

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

HBK Sorce Advisory Erie, Pennsylvania $5.18B AUM 12.38% 1-Year Est. Return

Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

RhumbLine Advisers's CAPR Position: Q3 2026 in Review

RhumbLine Advisers reduced its Capricor Therapeutics (CAPR) stake by 3.7% in Q3 2026, selling an estimated $27.5K and leaving 65,395 shares worth $619K. The position accounts for ﹤0.01% of the portfolio, ranked #2598.

RhumbLine Advisers first reported a position in CAPR in Q2 2024 and has held it in 10 quarters since. The position peaked at $1.63M in Q2 2026. 62 funds tracked by Wall St. Rank hold CAPR as of Q3 2026.

RhumbLine Advisers held 65,395 shares of Capricor Therapeutics worth $619K as of Q3 2026.
RhumbLine Advisers sold 2,486 Capricor Therapeutics shares in Q3 2026, an estimated $27.5K.
Capricor Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #2598 holding.
RhumbLine Advisers first reported a position in Capricor Therapeutics in Q2 2024 and has held it in 10 quarters since.
RhumbLine Advisers's Capricor Therapeutics position peaked at $1.63M in Q2 2026.
62 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.